MedTrace Logo

Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis

NCT02625246 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-08-28

No results posted yet for this study

Summary

To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy

Conditions

Interventions

BIOLOGICAL

hMSCs

intravenous infusion of bone marrow-derived allogeneic stem cells

Sponsors & Collaborators

  • Marilyn Glassberg

    lead OTHER

Principal Investigators

  • Glassberg K Marilyn, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-04
Primary Completion
2019-05-15
Completion
2019-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625246 on ClinicalTrials.gov